As incoming CHIME Board Chair, Scott MacLean hopes to help drive educational and networking opportunities, while also focusing on critical issues such as burnout and talent retention, he said in this interview. “The next wave of leaders needs to be prepared to face these challenges.”
In this podcast interview, Scott MacLean talks about “the fundamental infrastructure” that enables MedStar to deliver quality care, why he sought a position on CHIME’s Board of Trustees, and the enormous impact individuals can have by taking community walks.
In this podcast, Scott MacLean talks about how MedStar is carrying out its post-Covid strategy, the “never-ending battle” to keep systems upgraded and refreshed, and why the digital front door is about so much more than a portal.
A prominent CIO of a regional hospital system encountered the limitations of HIPAA and so-called “Protected Health Information (PHI)” when her boss fired her after a short medical leave of absence. After years working without taking vacation, a family catastrophe that affected her health prompted her to take a medical leave of absence. She had […]
The FDA has been receiving a great deal of criticism from the clinical community about a variety of issues, but probably none is as contentious as the ongoing patient safety issues regarding harmful drug-drug interactions and drug-gene interactions, estimated by the Institute of Medicine to cause 250,000 deaths each year in the U.S. The current […]
Individualizing drug therapy based on pharmacogenomics (PGx) is considered by many academic researchers and clinical experts as the “next significant domain of clinical practice” (see the American College of Clinical Pharmacology’s very informative web-based tutorial, “The Future of Medicine: Pharmacogenomics”, http://user.accp1.org/index_new.html). Drugs that are currently recommended for PGx testing by the FDA include specific medications […]
An HHS committee on Physician and Patient Education is developing new certification requirements for hospital physicians in genomics and pharmacogenomics. Most hospital physicians, unless your specialty is oncology or obstetrics, are not familiar with anything but diseases inherited as classical Mendelien traits. These new rules will require basic certification in both classical genetics and the […]
The Personal Health Record (PHR) should finally allow patients to control their own Protected Health Information (PHI), allow them to assign ‘agents’ such as parents acting for children, or, in the later stages of life, children acting for parents. Eventually the goal is to enable seamless integration with the EHR and allow patients access to […]
The Nationwide Health Information Network (NHIN) is still being defined by the Office of the National Coordinator’s Office for Health IT – more specifically the Health IT Policy Committee. The goal appears to be to build a new infrastructure using “a collection of protocols, legal agreements, specifications, and services that enables the secure exchange of […]
“The FDA considers both unwanted harmful effects and lack of efficacy to be adverse events. When considering candidates for pharmacogenomic relabeling, the FDA evaluates the severity of the adverse reaction, the degree to which genetics predicts the reaction, and the total number of individuals likely to be affected. These factors are important in assessing the […]